Lung Cancer Interception Research Team - Stand Up to Cancer
Help save a life

This holiday season, Mastercard is standing with us in the fight to end cancer as we know it. From now until December 31st, 2018, if you use a Mastercard to donate to Stand Up To Cancer, Mastercard will TRIPLE your gift, up to $300,000!

That’s triple the impact to support groundbreaking cancer research that will help save lives now!

$25 = $75
$50 = $150
$100 = $300
$250 = $750
GIVE FOR LIFE
For every $1 donated through StandUpToCancer.org with a Mastercard, Mastercard will donate $2, up to $300,000. Offer starts 12/14/18 at 12:01am ET and ends 12/31/18 at 11:59pm ET, or at the $300,000 max, whichever comes first.

Research Teams

Research  >  Research Portfolio  >  Dream Teams  >  Lung Cancer Interception Research Team

SU2C–LUNGevity–American Lung Association Lung Cancer Interception Research Team:
Blood-Based Early Interception of Lung Cancer

Grant Term: December 2017–November 2018

The SU2C-LUNGevity-American Lung Association (ALA) Lung Cancer Interception Research Team hypothesizes that the early detection of invasive lung cancers can be improved through new technological approaches, and that progress on this front can quickly bring about more effective patient treatments. The team is working to build a new tool―a composite of blood-based biomarker tests called the Lung Cancer Interception Assay―that can be used in conjunction with standard imaging to provide early detection of lung cancer.

ABOUT THIS TEAM’S RESEARCH

The SU2C–LUNGevity–ALA Lung Cancer Interception Research Team, building on the work of the SU2C Dream Team: Bioengineering and Clinical Applications of Circulating Tumor Cell Chip, is working to develop a Lung Cancer Interception Assay (LCIA). This test will examine circulating tumor cells and circulating tumor DNA in blood samples taken from patients, and will be used in conjunction with low-dose CT scans to provide early detection of lung cancer. If successful, the LCIA will be moved forward to larger, prospective clinical trials.

The Research Team hypothesizes that the early detection of invasive lung cancers can be improved through new technological approaches, and that progress on this front can quickly bring about more effective patient treatments.

MEET THE TEAM

The top scientists and researchers on the SU2C–LUNGevity–ALA Lung Cancer Interception Research Team come from a variety of backgrounds and disciplines, which leads them to great insights upon collaboration. Learn more about the SU2C–LUNGevity–ALA Lung Cancer Interception Research Team.

Team Members

Lecia V. Sequist, MD
Massachusetts General Hospital Cancer Center
Team Leader

Maximilian Diehn, MD, PhD
Stanford University School of Medicine
Co-leader

Chris Draft
Chris Draft Family Foundation
Advocate

PuiYee (Elaina) Chan, PhD
Massachusetts General Hospital
Project Manager

“It’s extremely frustrating that we’re not technically able to find lung cancer earlier in the majority of patients. We need to change the paradigm that we use to identify patients so that they are found early enough to offer them curative treatment. If we really want to save more lives from lung cancer, we have to exponentially improve our diagnostics.”

Lecia V. Sequist, MD
Massachusetts General Hospital Cancer Center

TEAM PROGRESS UPDATES

Stand Up To Cancer’s research projects are designed to foster collaborative, swift translational research. The hallmarks of these efforts include rigorous application and selection procedures, sufficient funding to allow scientists to focus on the objectives of the grant, and reviews by senior scientists every six months. These reviews help the investigators capitalize on the latest findings, address potential roadblocks, and collaboratively evolve as the science requires. Please click on the link to see summaries of research results so far for the SU2C–LUNGevity–ALA Lung Cancer Interception Research Team.

TEAM PROGRESS UPDATES

PUBLICATIONS

This team started its work in November 2017; links to publications will be posted when they are available.

CLINICAL TRIALS REFERRALS

Cancer clinical trials allow researchers to study innovative and potentially life-saving new treatments. The goal is to find treatments that are better than what’s currently available, in fact the therapies offered to today’s cancer patients were almost all studied and made possible by people participating in clinical trials. But many cancer clinical trials don’t get completed because not enough people participate.

At StandUpToCancer.org/ClinicalTrials, you’ll find information and answers to common questions about clinical trials. Learn more and talk to your doctor to see if a clinical trial may be the best choice for you.

You can also connect with EmergingMed, a free and confidential clinical trial matching service that provides access to a vast database to help you identify the clinical trials that might be right for you or your loved one.

LEARN MORE